Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

China Pharma Holdings (CPHI) EBT Margin (2016 - 2025)

China Pharma Holdings filings provide 16 years of EBT Margin readings, the most recent being 99.68% for Q4 2025.

  • On a quarterly basis, EBT Margin rose 829.0% to 99.68% in Q4 2025 year-over-year; TTM through Dec 2025 was 76.91%, a 2767.0% increase, with the full-year FY2025 number at 76.91%, up 2767.0% from a year prior.
  • EBT Margin hit 99.68% in Q4 2025 for China Pharma Holdings, down from 86.15% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 24.28% in Q1 2023 to a low of 155.48% in Q2 2024.
  • Median EBT Margin over the past 5 years was 54.54% (2023), compared with a mean of 63.26%.
  • Biggest five-year swings in EBT Margin: tumbled -10147bps in 2024 and later surged 10397bps in 2025.
  • China Pharma Holdings' EBT Margin stood at 33.94% in 2021, then dropped by -28bps to 43.28% in 2022, then plummeted by -32bps to 57.32% in 2023, then plummeted by -88bps to 107.98% in 2024, then rose by 8bps to 99.68% in 2025.
  • The last three reported values for EBT Margin were 99.68% (Q4 2025), 86.15% (Q3 2025), and 51.51% (Q2 2025) per Business Quant data.